Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

被引：2
|
作者：
Piccaluga, PP
Malagola, M
Rondoni, M
Amabile, M
Paolini, S
Soverini, S
Gaitani, S
Visani, G
Baccarani, M
Martinelli, G
机构：
[1] Univ Bologna, Inst Haematol & Med Oncol L&A Seragnoli, Bologna, Italy
[2] S Salvatore Hosp, Dept Haematol, Pesaro, Italy
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2004年 / 72卷 / 04期
关键词：
D O I：
10.1111/j.1600-0609.2004.00212.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：302 / 303
页数：2
相关论文
共 47 条
  • [1] Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias
    Nimmanapalli, R
    Bhalla, K
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (06) : 616 - 620
  • [2] The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients
    Piccaluga, PP
    Malagola, M
    Amabile, M
    Rondoni, M
    Paolini, S
    Pane, F
    Russo, D
    Visani, G
    Baccarani, M
    Martinelli, G
    HAEMATOLOGICA, 2004, 89 (10) : 1269 - 1271
  • [3] Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
    F Fei
    S Stoddart
    M Müschen
    Y-m Kim
    J Groffen
    N Heisterkamp
    Leukemia, 2010, 24 : 813 - 820
  • [4] Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
    Fei, F.
    Stoddart, S.
    Mueschen, M.
    Kim, Y-M
    Groffen, J.
    Heisterkamp, N.
    LEUKEMIA, 2010, 24 (04) : 813 - 820
  • [5] Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate
    Pornpetti, Franca
    Spadano, Antonio
    Sau, Antonella
    Mennucci, Antonio
    Russo, Rosa
    Catinella, Virginia
    Franchi, Paolo Guanciali
    Calabrese, Giuseppe
    Palka, Giandomenico
    Fioritoni, Giuseppe
    Iacone, Antonio
    LEUKEMIA RESEARCH, 2007, 31 (04) : 563 - 567
  • [6] Imatinib in combination with chemotherapy for newly diagnosed BCR/ABL-positive acute lymphoblastic leukemia in adults
    Ohno, R.
    Yanada, M.
    Naoe, T.
    ANNALS OF HEMATOLOGY, 2006, 85 : 84 - 86
  • [7] Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
    Feldhahn, Niklas
    Arutyunyan, Anna
    Stoddart, Sonia
    Zhang, Bin
    Schmidhuber, Sabine M.
    Yi, Sun-Ju
    Kim, Yong-mi
    Groffen, John
    Heisterkamp, Nora
    ONCOIMMUNOLOGY, 2012, 1 (05): : 618 - 629
  • [8] INCREASING BCR-ABL EXPRESSION LEVELS AND/OR OCCURRENCE OF ABL POINT MUTATIONS NOT ALWAYS PREDICT RESISTANCE TO IMATINIB MESYLATE IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Grammatico, S.
    Elia, L.
    Vitale, A.
    Matarazzo, M.
    Falciani, V
    Rago, A.
    Cenfra, N.
    Peluso, A. L.
    Pedace, L.
    Grammatico, P.
    Pane, F.
    Meloni, G.
    Foa, R.
    Cimino, G.
    HAEMATOLOGICA, 2008, 93 : S88 - S89
  • [9] Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia
    Ito, K
    Tominaga, K
    Suzuki, T
    Jinnai, I
    Bessho, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (03) : 242 - 245
  • [10] Successful Treatment with Imatinib Mesylate in a Case of Minor BCR-ABL-Positive Acute Myelogenous Leukemia
    Katsuro Ito
    Kazunori Tominaga
    Toshiya Suzuki
    Itsuro Jinnai
    Masami Bessho
    International Journal of Hematology, 2005, 81 : 242 - 245
12345